March 03, 2026

Miami Cancer Institute Leads Landmark Phase 2 Glioblastoma Trial

The randomized Phase 2 CRUX-2 trial (Ruxolitinib in Combination with Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma) is currently recruiting.

Baptist Health South Florida

February 27, 2026

Latest Clinical Evidence in Extensive-Stage Small Cell Lung Cancer Treatment

Discover the latest strategies in the treatment and management of extensive-stage small cell lung cancer, emphasizing the critical role of supportive care and advancements in therapy. - JADPRO Live.

JADPRO

February 27, 2026

Novel Therapies and Multidisciplinary Strategies in Metastatic Triple-Positive Breast Cancer

Explore the latest insights on treating metastatic triple-positive breast cancer, emphasizing multimodal therapy and adverse event management, as discussed by oncology experts at JADPRO Live 2025.

JADPRO

February 26, 2026

AHA Issues Pediatric Hypertriglyceridemia Statement

The scientific statement defines pancreatitis and atherosclerotic cardiovascular disease risk thresholds and outlines causes and management in youths.

Conexiant

February 24, 2026

Medicontur Premium Class – the global cataract & refractive community

Evidence-based, clinically driven, interactive, and accessible

The Ophthalmologist

February 23, 2026

Dissecting Standards

Examining the case for the regulation of grossing personnel

The Pathologist

February 20, 2026

Epcoritamab Plus R² in Follicular Lymphoma: A Potential New Treatment Standard

In patients with follicular lymphoma who received at least one prior line of therapy, the combination of the bispecific antibody epcoritamab-bysp and rituximab–lenalidomide (R2) reduced the risk of di...

The ASCO Post

February 20, 2026

A Practical Approach to Early-Phase CMC

Integrated, risk-based chemistry, manufacturing and controls strategies support early-phase development, writes Richard Chubb

The Medicine Maker

February 19, 2026

Lead Exposure Implicated in Rising Alzheimer's Rates

US study finds that patients with high bone lead levels are three times more likely to develop the disease

The Pathologist